Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aptose Bioscns
(TSX:
APS
)
0.5300
-0.0200 (-3.64%)
Streaming Delayed Price
Updated: 2:11 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aptose Bioscns
< Previous
1
2
Next >
Aptose Enters into $25 Million Committed Equity Facility
May 25, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
May 23, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the First Quarter 2023
May 08, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
May 04, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
April 24, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
April 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
March 28, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Fourth Quarter and Full Year 2022
March 23, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
March 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
March 09, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
March 02, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
January 30, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
December 28, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences Establishes New At-The-Market Facility
December 12, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
December 11, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
December 07, 2022
Data to be presented in poster at ASH Annual Meeting
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib
November 14, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting
November 03, 2022
Data for Tuspetinib (HM43239) and Luxeptinib Accepted for Poster Presentation
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Third Quarter 2022
November 01, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022
October 18, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.